drugset / Trial / NCT02893722

A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment

NCT02893722

Phase 1 Unknown 200 enrolled Shanghai First Maternity and Infant Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This study intends to carry out a prospective, randomized, double blind and controlled study to compare the influence of Atosiban and placebo on uterine contraction frequency, endometrial blood flow perfusion, oxytocin and serum concentration of PGF2α, embryo implantation rate and clinical pregnancy rate on the RIF population after fresh embryo transfer, so as to further clarify the curative effect of Atosiban in the treatment of RIF and provide evidence-based basis for Atosiban for application in RIF population.

Timeline

Start
2017-01
Primary completion
2018-01
Completion
2018-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atosiban Other / unclassified 37.5 mg Intravenous